Orla Dolan

So we do still have to fund research because that's a pipeline.

And then we get these exciting days, you know, five or 10 years out.

Yeah, so it looked like they saw a 20% shift in survival there, which for pancreatic cancer is amazing because we all know pancreatic cancer is a really poor prognosis or low survival cancer and doesn't really have a lot of options.

And so it got a standing ovation.

And I think to have over 1,200 oncologists standing on their feet, it tells you how excited they were.

So

So, look, I think in pancreatic cancer and other cancers, there's a lot of things coming out now, the culmination of years of research.

And it's an exciting time to be hearing about them and knowing these things are coming for the patients who need them.

Yeah, I mean, that is a challenge for more of the modern treatments, particularly biological ones, because if they're individualised, it does require a certain amount of sophistication in the background and they are costly.

But not all of them are.

And the prices of those things are coming down.

And I think if you can get this kind of long term results, that makes the case for why any government should want to support them and give them to patients.

What's amazing about this Moderna vaccine or the trial that they were talking about, this is about preventing reoccurrence.

So if you're putting people on this type of drug and this immunotherapy, you're not having to deal with all the advanced impact of that disease.

You're preventing it from ever happening again.

And I think that's the way we have to look at it.

How do we shift the dial to preventing these things recurring and therefore reoccurring?

We are saving money that way, too.

Yeah, I mean, we've believed at Breakthrough Cancer Research and many scientists have talked for a long time about the power of the immune system.

We've seen that immunotherapies, when they work for people, are incredible tools that stop cancer from coming back.